Roy D. Baynes, MD, PhD, to Join Gilead Sciences as Senior Vice President, Oncology Therapeutics
January 18 2012 - 4:40PM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Roy D.
Baynes, MD, PhD, will join the company as Senior Vice President,
Oncology Therapeutics. In this position, Dr. Baynes will report to
Norbert W. Bischofberger, PhD, Executive Vice President, Research
and Development and Chief Scientific Officer and will have
responsibility for Gilead’s programs in oncology. Dr. Baynes will
also join Gilead’s Executive Committee.
“Roy’s appointment reflects our commitment to building a leading
oncology research and development program, and I am very pleased to
welcome him to the Gilead team,” said Dr. Bischofberger. “Roy has
an extensive background in clinical practice, academic research and
in cancer drug development. Under his leadership, we are well
positioned to advance our growing number of pipeline programs
targeted at both hematological malignancies and solid tumors.”
Dr. Baynes joins Gilead from Amgen, where he served as Vice
President, Global Development and Therapeutic Area Head Hematology
Oncology. He led the Clinical Development and Medical Affairs teams
responsible for the approval and/or launch of numerous hematology
and oncology products over the last decade. Prior to joining Amgen
in 2002, Dr. Baynes was the Charles Martin Professor of Cancer
Research at the Barbara Ann Karmanos Cancer Institute at Wayne
State University in Detroit, where he also held the positions of
Professor of Medicine, Professor of Oncology and Director of the
Bone Marrow Transplant Program.
“I’ve long admired Gilead’s scientific approach and am excited
to join the company at a time when it is rapidly building its
presence in oncology through acquisitions and innovative
partnerships,” said Dr. Baynes. “Cancer research is an incredibly
challenging and evolving field, but one with great opportunity and
I look forward to working closely with the internal team and
external collaborators as we seek to develop novel cancer therapies
that address significant unmet medical needs.”
Dr. Baynes received his medical degree and doctorate in
philosophy from the University of the Witwatersrand in South
Africa, and completed his medical training in the Department of
Hematology and Oncology at Johannesburg Hospital. He is a member or
fellow of several medical societies and has published more than 200
peer-reviewed articles and abstracts.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers,
develops and commercializes innovative therapeutics in areas of
unmet medical need. The company’s mission is to advance the care of
patients suffering from life-threatening diseases worldwide.
Headquartered in Foster City, California, Gilead has operations in
North America, Europe and Asia Pacific.
For more information on Gilead Sciences, please
visit the company’s website at www.gilead.com or call Gilead Public
Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2024 to Jun 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2023 to Jun 2024